Dennis Steverson1,2, Ling Tian2, Yuchang Fu2, Wei Zhang2, Elizabeth Ma2, William Timothy Garvey2,3. 1. 1 Department of Pathology, University of Alabama at Birmingham , Birmingham Alabama. 2. 2 Department of Nutrition Sciences, University of Alabama at Birmingham , Birmingham Alabama. 3. 3 Birmingham Veterans Affairs Medical Center , Birmingham, Alabama.
Abstract
BACKGROUND: Insulin resistance is central in the pathophysiology of cardiometabolic disease; however, common mechanisms that explain the parallel development of both type 2 diabetes and atherosclerosis have not been elucidated. We have previously shown that tribbles homolog 3 (TRB3) can exert a chronic pathophysiological role in promoting insulin resistance and also has an acute physiological role to alternatively regulate glucose uptake in fat and muscle during short-term fasting and nutrient excess. Since TRB3 is expressed in human atherosclerotic plaques, we explored its role in foam cell formation to assess its potential contribution to atherogenesis. METHODS: We have used human THP-1 monocytes, which transition to lipid-laden macrophage foam cells when exposed to oxidized low-density lipoprotein (ox-LDL). RESULTS: We first observed that TRB3 was upregulated by more than twofold (P < 0.01) within 24 hr of treatment with ox-LDL. To determine whether TRB3 actively participated in foam cell formation, we overexpressed TRB3 in THP-1 monocytes and found that this led to a 1.5-fold increase in cholesterol accumulation after 48 hr (P < 0.01), compared with controls. At the same time, TRB3 overexpression suppressed inflammation in macrophages as evidenced by reduced expression and secretion of tumor necrosis factor alpha (TNF-α) and interleukin-1 beta (IL-1β) (both P < 0.01). CONCLUSIONS: (1) TRB3 is upregulated in macrophages upon treatment with ox-LDL; (2) TRB3 promotes lipid accumulation and suppresses cytokine expression; and (3) inflammation and foam cell formation can be reciprocally regulated, and TRB3 orients the macrophage to assume a more primary role for lipid accumulation while maintaining a secondary role as an inflammatory immune cell.
BACKGROUND:Insulin resistance is central in the pathophysiology of cardiometabolic disease; however, common mechanisms that explain the parallel development of both type 2 diabetes and atherosclerosis have not been elucidated. We have previously shown that tribbles homolog 3 (TRB3) can exert a chronic pathophysiological role in promoting insulin resistance and also has an acute physiological role to alternatively regulate glucose uptake in fat and muscle during short-term fasting and nutrient excess. Since TRB3 is expressed in humanatherosclerotic plaques, we explored its role in foam cell formation to assess its potential contribution to atherogenesis. METHODS: We have used humanTHP-1 monocytes, which transition to lipid-laden macrophage foam cells when exposed to oxidized low-density lipoprotein (ox-LDL). RESULTS: We first observed that TRB3 was upregulated by more than twofold (P < 0.01) within 24 hr of treatment with ox-LDL. To determine whether TRB3 actively participated in foam cell formation, we overexpressed TRB3 in THP-1 monocytes and found that this led to a 1.5-fold increase in cholesterol accumulation after 48 hr (P < 0.01), compared with controls. At the same time, TRB3 overexpression suppressed inflammation in macrophages as evidenced by reduced expression and secretion of tumor necrosis factor alpha (TNF-α) and interleukin-1 beta (IL-1β) (both P < 0.01). CONCLUSIONS: (1) TRB3 is upregulated in macrophages upon treatment with ox-LDL; (2) TRB3 promotes lipid accumulation and suppresses cytokine expression; and (3) inflammation and foam cell formation can be reciprocally regulated, and TRB3 orients the macrophage to assume a more primary role for lipid accumulation while maintaining a secondary role as an inflammatory immune cell.
Authors: Jingti Deng; Christian H James; Lisa Patel; Alberto Smith; Kevin G Burnand; Hassan Rahmoune; Jonathan R Lamb; Bill Davis Journal: Clin Sci (Lond) Date: 2009-02 Impact factor: 6.124
Authors: Cameron R Stewart; Lynda M Stuart; Kim Wilkinson; Janine M van Gils; Jiusheng Deng; Annett Halle; Katey J Rayner; Laurent Boyer; Ruiqin Zhong; William A Frazier; Adam Lacy-Hulbert; Joseph El Khoury; Douglas T Golenbock; Kathryn J Moore Journal: Nat Immunol Date: 2009-12-27 Impact factor: 25.606
Authors: Priyamvada M Pitale; Irina V Saltykova; Yvonne Adu-Agyeiwaah; Sergio Li Calzi; Takashi Satoh; Shizuo Akira; Oleg Gorbatyuk; Michael E Boulton; Machelle T Pardue; W Timothy Garvey; Mohammad Athar; Maria B Grant; Marina S Gorbatyuk Journal: Diabetes Date: 2021-05-11 Impact factor: 9.337
Authors: Laura Martinez-Campesino; Klaudia Kocsy; Jaime Cañedo; Jessica M Johnston; Charlotte E Moss; Simon A Johnston; Stephen Hamby; Alison H Goodall; Jessica Redgrave; Sheila E Francis; Endre Kiss-Toth; Heather L Wilson Journal: Front Cardiovasc Med Date: 2022-08-26